Loading...
Loading...
Supernus Pharmaceuticals,
Inc.
SUPN, a specialty pharmaceutical company focused on developing
and commercializing products for the treatment of central nervous system
diseases, today announced the issuance of a fifth patent (number 8,889,191) by
the United States Patent and Trademark Office (USPTO) covering Trokendi XR,
its novel once-daily extended-release topiramate product. The patent provides
protection for the product with expiration that is no earlier than 2027.
"We are very serious about securing intellectual property protection for our
innovative products. This is now the second patent that issued this month on
Trokendi XR. We will continue to build our patent estate to provide our
products with the protection they are entitled to. We now have patent
protection on Oxtellar XR® and Trokendi XR® through four and five issued U.S.
patents, respectively," said Jack A. Khattar, President and CEO of Supernus.
Supernus has several additional patent applications for extended-release
topiramate and extended-release oxcarbazepine pending in other geographic
regions.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in